



French Healthcare Corner

J.P. Morgan Healthcare Week

January 2023

A pro-business agenda

making France more resilient and attractive for investors and international talents.

1)

Solid fundamentals stimulating competitiveness and innovation

Since 2017, the French government has been committed to a program of flagship structural reforms to transform the economy, the lives of businesses and boost competitiveness through:



A new tax environment

Drastic reduction in corporate tax rate (from 33% to 25% by 2022) and production taxes (- €10 billion/year starting January 2021), flat tax of 30% on capital revenues, competitive taxation of R&D (corporate tax rate at 10% for revenues from IP, research tax credit equivalent to 30% of R&D expenditure).



A transformation of the French social model

Leading to greater flexibility and predictability (simplification of dismissals for economic reasons, facilitation of social dialogue), lower social security contributions on low salaries, adaptation of skills to the new needs of the economy (€15 billion Skills investment plan).



An acceleration of business setups

Simplification of administrative procedures for industrial setups (Acceleration and Simplification of Public Action Act), **127 ready-to-use sites** available for investors, removed obstacles to growth in businesses (Action Plan for Business Growth and Transformation Act).



An attractive ecosystem for international talents

Attractive personal tax regime for international talents (specific expatriation scheme for up to eight years, up to 50% of the total remuneration exempted), dedicated procedures for entering and working in France (Talent passport, French Tech Visa Scheme), dedicated Business France's desk answering global mobility related questions from international tech talent (**Welcome to la French Tech**).

2)

Unprecedented public investments for the recovery and to shape the France of 2030



A massive emergency economic plan of €470 billion, of which €300 billion in state-guaranteed loans, implemented from the onset of the global health crisis to protect businesses and their employees.

The “Relaunch France” economic stimulus plan (€100 billion, of which 70% was spent by the end of 2021) to provide further support over the period 2020-2022 in strategic sectors, including healthcare, and with priority intervention to boost ecological transition.

A new investment plan “France 2030” unveiled by the President of France on October 12, 2021 to complete the cycle of reforms enabling France to transform itself and become more attractive. Backed by €30 billion, of which €3.5 billion will be disbursed by 2022, France 2030 is an ambitious continuum of public support to fast-track the emergence of breakthrough innovations and support their industrialization, especially in key sectors for tomorrow’s healthcare.

3)

Strong results with a recovery already achieved

THESE FAR-REACHING CHANGES AND MASSIVE PUBLIC SUPPORT ALLOW FRANCE TODAY TO POST:



A renewed and maintained investor confidence, with France remaining the most attractive European country to foreign investors for the second year in a row in 2020. (EY, 2021)



A robust labor market, with an unemployment rate due to reach 7.6% by the end of 2021, the lowest since 2008 (INSEE), as well as 231,000 industrial jobs created or supported between September 2020 and August 2021.



A growth forecast of 6.3% in 2021 (versus 5% in the euro zone, according to IMF).



A rediscovered optimism, with business profit shares higher than they were in 2018 (INSEE) and a default rate of businesses that needed a state-guaranteed loan since March 2020 less than 0.6% (Banque de France).

1) A constantly evolving, living ecosystem



“ France has today made a choice. That of not being a country that sees healthcare innovations being designed and developed elsewhere, but of being a country that is taking its destiny in its own hands and is assuming the risk of innovating, inventing, manufacturing and selling tomorrow’s healthcare products and solutions worldwide. We have everything we need to succeed - the skills and the talent. And now we also have a plan and the resources.

Emmanuel Macron,
French President ”

Major improvement in **market access**



OBJECTIVE

Achieving a market **access time** for medicines and medical devices **lower than the European targets.**



ACTION

Immediate market access after the validation by the French National Health Authority (HAS) for all products assessed with an “Improvement in Actual Medical Benefit” (IAMB/ ASMR) ranked I to IV, with a two-year test period.

Market **growth**



OBJECTIVE

An ambition of **2.4% annual growth** set until 2024 for expenditure on drugs and healthcare products in the National Objective for Healthcare Expenditures.



ACTION

An increase of **€1 billion** for expenditures on drugs and medical devices, announced by the Minister for Health in September 2021, and an extension of the criteria for reimbursement of medicinal products and medical devices, in addition to hospital rates, when the Improvement in “Actual Medical Benefit” is significant.

Rewarding **investments** in France



OBJECTIVE

To reinforce and better support investments in France and the EU (R&D and production) when fixing medicinal product prices through financial incentives.



ACTION

The bill on the funding of the social welfare for 2022 doubles financial support from €150 million to **€300 million**.

An improved **early access scheme reform**

France offers **one of the most open and efficient early-access schemes** for new therapeutics in Europe.

Two New access paths (early access and compassionate access) leading to a single set of access rules, reimbursement and faster granting.

Greater visibility and predictability for businesses and faster access for patients to the latest innovations, especially biotherapies.

1.1) A stimulus plan focused on **health**

Announced last June, the French government's **Healthcare Innovation 2030** devotes a significant portion of its investments to the health sector - €7 billion between now and 2030.

The overall ambition is to make France the leading European nation in terms of healthcare innovation and sovereignty, particularly in terms of biomedical research, clinical trials and, more generally, disruptive innovations in the health sector, through the development of biotherapy and support for

specialist healthcare startups, in order to achieve "a medicine that is more predictive, more preventive and more innovative."



20

New medicines to treat cancer and chronic illnesses

1.2) **€7 billion** of state investment by 2030

	Transversal support for research : cluster policy, attractiveness of high level researchers, support for infrastructures.	€1 BILLION
	Transversal support for technology maturation and clinical trials .	€500 MILLION
	Acceleration strategies for biotherapies, digital health and emerging infectious diseases	€2 BILLION
	Support for industrial investment through calls for projects and an European IPCEI project.	€1.5 BILLION
	Support for emergence growth and industrialization of startups by Bpifrance	€2 BILLION

1.3) An **economically stable** sector

In 2019, the French pharmaceutical industry generated €60 billion. It is the fifth largest market worldwide for drugs.

The country has been so well placed for years partly due to a social security system that provides easy access to care for its 67 million citizens.



146 projects

Already supported in 2021 for a total investment of €1.25 billion



EY 2021 Attractiveness Survey

#1 in Europe

for the second year running

France has very generous state funding for R&D, with tax breaks such as the **research tax credit, innovation tax credit and the**

innovative new companies status, but also innovation funding programs such as the Major Investment Plan.



France, #1 country for R&D subsidies within OECD countries thanks to the research tax credit, covering 30% of R&D expenses up to €100 million

Source: OECD

France is Europe's **most attractive country in terms of its research tax credit** (*crédit d'impôt recherche – CIR*) which is a tax-incentive scheme to support research that is open to businesses of any size and from any sector: **30% of R&D expenses up to**

€100 million and 5% above, reimbursed or paid through corporate tax (highest R&D spending tax subsidy rate in OECD countries).

2) French HealthTech: A European innovation leader

2.1) A **priority** for the government

All these investments are designed to boost an already healthy ecosystem. In 2021, France has over 2,000 startups in the health sector employing 50,000 people.

In order to further encourage the marketing of innovations, the Health Plan 2030 provides for a series of adapted measures, namely – accelerating the launch of innovations on the market, facilitating the implementation of clinical trials and promoting joint projects between public and private entities.

Prioritizing the **three areas** that will make up the healthcare system of tomorrow:



Biotherapy and
bioproduction



Digital health



Research into emerging
infectious diseases and
chemical, biological, radiological
and nuclear threats



Oncology:
#1 area investigated
by French Biotech



Strong expertise
in **rare diseases**

2.2) Prioritize investments to focus on **future technologies**



€650 million

To move to 5P medicine thanks to digital technology and to **create French champions.**



€750 million

To **prepare for pandemics** and have the means to respond to them in the country.



€1 billion

To strengthen our **biomedical research** capacity.



Simplification and speeding up of the **clinical trial authorization system.**



Develop our **methodological and operational expertise** in new types of clinical trials.

2.3) State of **the health sector** in France



2,000 startups
inc. 750 biotech; 1,100 medtech;
200 e-health businesses
50,000 jobs in 2021



4,000+ medical innovations being developed or already on the market
inc. 1,900 arising from biotechnology and 2,200 medical devices.



52% of Healthtech businesses were created from academic or public research



400 digital health products



13 Nobel prizes



35,000 patents filed this year

Source: Panorama France Biotech, 2020



The Health Innovation Plan 2030, beyond parametric reforms, affects all levers, transforms the healthcare ecosystem and facilitates the development, production and access to healthcare innovations in France. It draws lessons from the crisis by supporting the creation of a solid and innovative industrial base in the sector of drugs and medical devices to meet the healthcare challenges of tomorrow.

Agnès Pannier-Runacher
Minister Delegate reporting to the
Minister for the Economy, Finance
and the Recovery, with responsibility
for Industry

3) An international development strategy



“ My mission consists mainly in identifying French talents based abroad or internationally and encouraging them to participate in our medical innovation ecosystem, whether in biotech, medtech or e-health.

Dr. Rafaèle Tordjman ”

3.1) A strong presence outside France

France has implemented a number of measures to increase its visibility among investors and talents.

To make France the leading innovative nation in healthcare in Europe, the French biotech ecosystem has nominated a special envoy, Dr. Rafaèle Tordjman, Head of the Venture Capital Fund Jeito Capital.

By organizing meetings like the Health Tech innovation days in Paris last October, France is **facilitating exchanges between businesses and investors**.



+155
Healthcare businesses
selected



+300
International investors



+15
Pharmaceutical
and industrial groups



20
Conferences
with 80 experts



1,300
Networking events
and private meetings

3.2) French Health Tech, a constant presence on the international scene



With the support of Business France and French Healthcare, French businesses ensure a presence **at all global events**. From Dubai to Dusseldorf, French Health Tech is making itself known.

At the J.P. Morgan conference, no less than **30 French businesses** will present their projects.

3.3) Greater attractiveness for foreign investors



€7.3 billion
invested in R&D in 2020



€2 billion
invested in the French
manufacturing base in 2020



Almost 500
healthcare investment projects
identified since 2015.




Healthcare: 18%
of total investment by foreign
businesses in R&D centers in France.



Pharma/Medtech: 40%
increase in total investment by foreign
businesses in 2020 versus 2019.

FRANCE IS THE MOST ATTRACTIVE COUNTRY IN EUROPE FOR FDI



Source: EY, European Investment Monitor, 2021

MEET OUR DELEGATION AT THE FRENCH HEALTHCARE CORNER DURING 2023 J.P. MORGAN HEALTHCARE WEEK

- Biotech & Pharma -

Cell Therapy

Immune system

Lupus

Inflammation



BIOSENIC

BioSenic is a late-stage biotechnology company specialized in the **use of arsenic salts for the treatment of autoimmune diseases and graft-versus-host disease (GvHD)**.

Its leading drug candidate is currently under Phase III clinical preparation (essentially in US centers). With an innovative approach, BioSenic aims at correcting the immune system's malfunction and runaway behavior at the source. The company is raising funds to finance clinical trials.



Meet BioSenic Table 1



alexia.rieger@medsenic.com



biosenic.com/



BIOSENIC S.A.



[@BioSenicSA](https://twitter.com/BioSenicSA)



4P-PHARMA

4P-Pharma is a clinical stage company dedicated to **regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases**. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities combined with Single Product Vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.

✉ **Contact:** revital@4p-pharma.com

🌐 www.algotx.com



ALGO TX

AlgoTx develops **novel treatments for complex pain**. ATX01 is a Phase 2 topical treatment for Chemotherapy-Induced Peripheral Neuropathy under an extensive IP portfolio and Fast Track designation from the FDA. The phase 2 study will recruit its first patient by year-end and finish in 2024. The company is raising funds to move to the Phase 2 of its Clinical development in CIPN, and POC in erythromelalgia.

✉ **Contact:** stephane@algotx.com

🌐 www.algotx.com



ALZPROTECT

Alzprotect is engaged in the **development of small compound candidate drugs for the treatment of neurodegeneration**. It develops the first drug for the treatment of Alzheimer's disease and PSP via Progranulin level increase: AZP2006. This pleiotropic compound not only counteracts Neurodegeneration but can potentially reverse the process. AZP2006 has achieved Phase 2a for the treatment of PSP for which it has obtained the Orphan Drug Status. The company is currently looking for Financing clinical pivotal phase 2/3 for PSP.

✉ **Contact:** p.verwaerde@alzprotect.com

🌐 www.alzprotect.com

Neurology

Parkinson



LYS THERAPEUTICS

Lys Therapeutics is a preclinical-stage biotechnology company pioneering a **revolutionary approach to treat neurological diseases through antagonism of tPA-NMDAr interaction in the blood vessels**, leading to restoration of NMDAr and blood-brain barrier physiological functioning, hence counteracting the associated neuroinflammatory and neurodegenerative processes. The company is looking to raise funds for the 1st Phase of its clinical trial.



Meet Lys Therapeutics Table 2



mblanc@lystherapeutics.com



lystherapeutics.com



[Lys Therapeutics](https://www.linkedin.com/company/lystherapeutics)



APMONIA THERAPEUTICS

Apmonia Therapeutics develops a first-in-class pipeline of **next-generation peptide-based therapies targeting the tumor microenvironment** to improve the lives of patients with cancer. Its lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1) in order to prevent CD47 receptor activation. The company is looking to finance its first clinical phases (Phase 1/2a) as well as lifecycle management activities and R&D activities on new products.

✉ [Contact: a.jeanne@apmonia-therapeutics.com](mailto:a.jeanne@apmonia-therapeutics.com) 🌐 apmonia-therapeutics.com



BIOPHYTIS

Biophytis is a clinical-stage biotechnology company specialized in the development of **therapeutics that are aimed at slowing the degenerative processes associated with aging** and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.

✉ [Contact: stanislas.veillet@biophytis.com](mailto:stanislas.veillet@biophytis.com) 🌐 www.biophytis.com



CILCARE

CILcare has 8 years of leadership in the understanding of **hearing disorders mechanisms** and has **developped a Smart R&D platform** with powerful data set, proprietary algorithms and a portfolio of drug candidates. A first compound is ready to enter phase IIa with a focus on identifying and treating the early sign of age-related hearing loss in very specific sub-patient groups. CILcare is currently looking to start 4 Phase IIa in the US and Europe, and plans on expanding its R&D platform with AI-driven technology.

✉ [Contact: celia.belline@cilcare.com](mailto:celia.belline@cilcare.com) 🌐 www.cilcare.com

Stem Cell therapy

Septic Shock

ARDS



STEMINOV

StemInov is developing an **off-the-shelf immunomodulation and adaptive cell therapy, based on WJ-MSC**, to tackle the complexity of an inflammatory disease as a first indication: septic shock and ARDS. It is the 1st large-scale GMP production unit, ensuring affordable treatment is on its way. StemInov is raising funds in order to set up of the GMP large scale production facility and conduct of phase 1/2a in septic shock and ARDS.



Meet StemInov Table 3



jhutin@steminov.com



www.steminov.com



StemInov



GENOSCIENCE PHARMA

Genoscience Pharma develops unique **small molecules in Oncology**. The company focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions. This is the first clinical stage company with unique lysosomotropic agents assessed in a global clinical trial. Genoscience Pharma is looking the finance to finance the next Phase of its development (Phase 2 CTA).

✉ [Contact: phalfon@genosciencepharma.com](mailto:phalfon@genosciencepharma.com)

🌐 www.genosciencepharma.com



LINKINVAX

LinKinVax offers an **universal, safe, enduring, vaccine platform** allowing the fast development of a wide range of prophylactic and therapeutic vaccines against multiple pathogens and cancer. Based on a Nobel Prize winning discovery, the vaccines platform is a proven, easy to produce, monoclonal antibody targeting dendritic cells to trigger an immune response. It addresses specific pathogens through antigens modulation. The company is currently looking to finance clinical phases for 2 products.

✉ [Contact: andre.auberton@linkinvax.com](mailto:andre.auberton@linkinvax.com)

🌐 www.linkinvax.com



MABLINK

Mablink Bioscience aims at transforming **cancer therapy using next-generation antibody-drug conjugates (ADCs)**. It leverages a proprietary technological innovation "PSARlink™": a unique linker structure, which confers a stealth properties to ADCs translating into improved pharmacological properties both in terms of anti-tumoral efficacy and tolerability. The potential of its technological platform has attracted the interest of innovative companies such as Emergence Therapeutics, which obtained in October 2021 a license to use Mablink's linkers to develop an ADC as a potential anti-cancer therapy. Mablink is now looking to fund the development of follow on ADCs based on Mablink's proprietary ADC platform.

✉ [Contact: jg.lafay@mablink.com](mailto:jg.lafay@mablink.com)

🌐 www.mablink.com

Endocrinology

Neuropsychiatry

Gynecology

Oncohematology

Gastroenterology

H·A·C·Pharma

H.A.C. PHARMA

H.A.C. Pharma **commercializes its own drugs in 6 European countries** (Spain, Italy, Belgium, Austria, Switzerland, Portugal) and works with a **network of trusted distributors** to cover top European countries. Its drugs are mainly promoted in the area of endocrinology, neuropsychiatry, gynecology, onco-hematology and gastroenterology. In 2022, BNP PARIBAS and TURENNE HEALTHCARE entered as minority shareholders in H.A.C. Pharma's capital and 3 Executive Directors were recruited to boost the development of the company through mainly acquisitions and geographical expansion.

4

Meet H.A.C. Pharma Table 4



philippe.bissay@hacpharma.com



www.hacpharma.com



H.A.C. PHARMA



V.E.R.A. BIOTECH

The startup V.E.R.A specializes in the **valorization of all the co-products of the coffee industry**. Its main activities are:

1. The extraction of high added value molecules from coffee co-products as a whole.
2. The development of materials based on coffee grounds and other vegetable co-products that are 100% biosourced and compostable at home.
3. The commercialization of a coffee fruit extraction as an antioxidant rich food supplement on the European, North and South American markets.

✉ **Contact: vera@vera-biotech.co**

🌐 **www.vera-biotech.co**

- Medtech -

Neurology

Anesthesia



BRAININDEX

Brainindex has developed a **smart integrated brain sensor** that allows clinicians to objectively **assess the effects of drug during general anesthesia**. This portable integrated monitoring platform with multi-measurement sensors, offers a solution for both intra-operative monitoring and post-operative screening of brain functioning. It can be used for all kinds of surgery, individualizes patient care and prevents postoperative delirium. Brainindex is looking to raise funds for its clinical, regulatory and commercial traction validation both in the US and in Europe.

5

Meet BrainindexTable 5



thierry.cussac@braindex.fr



braindex.fr



Braindex-sas



ABL DIAGNOSTICS

ABL Diagnostics develops **proprietary genotyping detecting mutations associated with drug resistance, virulence, and vaccine escape** by sequencing assays in infectious diseases. It includes the largest pipeline with targeted sequencing and Whole Genome for HIV, Hepatitis B and C, Tuberculosis, Covid-19, Herpes, Cytomegalovirus, and more. The company is currently looking to reinforce its commercial and R&D efforts in Europe, establish commercial affiliates in North America, Africa and Asia.

✉ **Contact: chalom@ablsa.com**

🌐 **www.abldiagnostics.com**



DIAGANTE

DIAGANTE develops a **solution for in vitro diagnostics**. Its platform allows the analysis of solid clinical specimen on rapid and high throughput instruments in clinical pathology labs. It provides faster results, enhanced personalized medical care, and lower costs to the stakeholders. The company is looking to learn more about the North American market, especially regarding commercialization and post-market clinical trials.

✉ **Contact: cecile.chevalier@diagante.com**

🌐 **www.diagante.com**



PHYSIOFLOW

PhysioFlow® is a unique range of **non-invasive hemodynamic monitors** that provide the **world's most accurate and validated measurements of cardiac output** and related parameters, even during maximal exercise. PhysioFlow® also measures arterial stiffness in a user-friendly, fast and reliable way. The company is looking to develop its sales and build new strategic partnerships.

✉ **Contact: f.bour@physioflow.com**

🌐 **www.physioflow.com**

Healthtech

4D Dentistry



MODJAW

MODJAW is a revenue-stage leader in the development and commercialization of **proprietary prosthetics and orthodontics treatments hardware and software solutions**. Its Tech-In-Motion™ solution harnesses all JAW Morphodynamics data. It provides real time virtual patient within minutes and opens the way to predictable personalized dental treatments while drastically cutting down the costs and time to operate. Now installed in 380+ offices in Europe and the US, MODJAW's solution is compatible with all dental scans and labs CAD designs software.

6

Meet MODJAW Table 6



arodrigue@modjaw.com



www.modjaw.com



MODJAW



@ModjawOfficiel



UROMEMS

UroMems uses **embedded robotic methods and smart systems to treat urinary incontinence**. Designed by urologists and collaborating scientists and engineers, UroActive™ intends to provide a new standard of care combining safety, efficacy, durability and ergonomics fitting any individual's lifestyle and anatomy. The company has received several awards for its innovation, including the Prix Galien Medstartup. The company is looking to raise more funds for clinical trials purpose.

✉ **Contact: hamid.lamraoui@uromems.com** 🌐 **www.uromems.com**

- Digital Health -

Surgery 4.0

Orthopedic



ABYS MEDICAL

Abys Medical is the only company in the world that created an entire holistic solution for surgery procedure management natively structured with cloud computing technologies. Surgiverse® is a disruptive **cloud core 3D solution with a holographic assistance** that improves surgical planning and organization of care through better pre-operative communication free-upping medical time, reducing operating time and patient length of stay. After settling its subsidiary in Canada, the company is looking to strengthen its connection with the North American market.

7

MeetAbys Medical Table 7



adestainville@abys-medical.com



www.abys-medical.com



Abys Medical



@AbysMedical



ENSWEET CARDIO

Ensweet Cardio is the **first medical grade solution** (CE class I MDD) **allowing a complete remote cardiac rehabilitation**. Its key advantage is to embed into 1 solution 6 key features focus on safety and quality of the care. Ensweet has quickly proven its relevance by convincing the Assurance Maladie (French health care agency) to launch a reimbursement process. The company is looking to expand its activities internationally.

✉ [Contact: fabien.watreLOT@ensweet.fr](mailto:fabien.watreLOT@ensweet.fr) 🌐 www.ensweet.fr



EPIGENE LABS

Epigene Labs is creating the **intelligence-augmenting solution for precision oncology research and drug development**. Designed by cancer scientists for cancer scientists, the company's platform (mCUBE) accelerates data-driven drug discovery, biomarker identification and patient selection - to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs already counts numerous partners such as Institut Curie, iTeos Therapeutics, Servier, and UCSF. It is currently raising funds to officially launch its technology platform.

✉ [Contact: akpeli@epigenelabs.com](mailto:akpeli@epigenelabs.com) 🌐 www.epigenelabs.com

The logo for Moonalisa is a solid orange rounded square with the word "moonalisa" written in a white, lowercase, sans-serif font.

moonalisa

MOONALISA

Moonalisa reinvents women's sleep care, a \$70B market. Providing teleconsultations, digital therapy, and coaching to female employees, it is a **virtual sleep clinic**. Its personalized sleep care programs are powered by the first-of-its-kind sleep care solution for women. The company is currently looking to commercialize the product towards US employers.

✉ [Contact: victor.v@moonalisa.co](mailto:victor.v@moonalisa.co) 🌐 www.moonalisa.co

Neurology

Dermo Cosmetics

Electrophysiology

3D Cell Culture



NETRI

NETRI is an industrial start-up that designs and manufactures **standardized neuro organs-on-chip for life-science companies** focused on neurological disorders, pain and dermo-cosmetics. NETRI's products and services are used to anticipate the efficacy of innovative treatments, accelerate preclinical research phases, and reposition compounds on new indications, all the while limiting animal testing. In 2022, NETRI secured a Series A funding of 8 million euros and is currently closing a Series B round to support its industrial and international growth.



Meet NETRI Table 8



Thibault.honegger@netri.com



netri.com



Netri



@NETRIF



TECH2HEAL

Tech2heal **SaaS platform** allows doctors to finetune **care workflows** to their needs and protocols, either creating remote care programs from scratch or by leveraging existing protocols from leading healthcare organizations. These workflows are then instantly transformed into device agnostic patient applications, empowering patients to manage parts of their care journey themselves. Meeting the needs of a growing patient population, Tech2heal solutions reduces the likelihood of hospital admission and improves clinical outcomes without adding an extra burden on clinical teams.

✉ **Contact: fabrice@tech2heal.com**

🌐 **www.tech2heal.com**



WHITELAB GENOMICS

WhiteLab Genomics develops and operates an **AI platform to assist biotech and pharma companies accelerate the discovery and design of genomic therapies**. Based on exhaustive datasets, the platform provides in-silico simulations to discover and design optimized payloads and vectors. The company is looking for an acceleration and international expansion.

✉ **Contact: ddebourgo@whitelabgx.com** 🌐 **whitelabgx.com**

- Transversal -



INSERM TRANSFERT

Inserm Transfert is the **1st academic biomedical research organization in Europe** with 1,000 research teams and more than 350 research units and clinical investigation centers. Transferring knowledge from Inserm's research laboratories to industry, it is also the 2nd applicant in the biotechnology field at the EPO and 3rd in the pharmaceutical field (ranking 2021), with a portfolio of more than 2,100 active patent families. The organization is looking for new licensing and industrial partnerships.

✉ **Contact: armelle.serose@inserm-transfert.fr**

🌐 **www.inserm-transfert.fr**

Huge thanks to our partners for their support

大成 DENTONS

Dentons is the world's largest law firm, delivering quality and value to clients around the globe. Dentons is a leader on the Acritas Global Elite Brand Index, a BTI Client Service 30 Award winner and recognized by prominent business and legal publications for its innovations in client service, including founding Dentons Global Advisors. Dentons' polycentric approach and world-class talent challenge the status quo to advance client interests in the communities in which we live and work.



French Tech is the name used to describe all actors of the French startup ecosystem in France and abroad. Members of this ecosystem include French entrepreneurs, startups, investors, business angels, engineers, etc. all working to develop startups and technology. French Tech Boston brings together over 60 entrepreneurs, from publicly traded companies to bootstrapped startups and ambitions to shed some light of the French Tech ecosystem in Boston.



LallianSe is pioneering and initiating the concept of life sciences integrator by turning innovations onto economic successes through the setup, operation, and execution of compelling equity stories. Deeply immersed in the hospital care, LallianSe aims at building the foundations for better health within its hospital- based coworking spaces, education programs, dedicated events and its Experts and Entrepreneurs- in-residence, tailored to each ambitious venture.



French Healthcare is an innovative public-private initiative aimed at bringing together all the players in the French healthcare ecosystem (businesses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world. This initiative is supported by the Ministry for Europe and Foreign Affairs, the French Healthcare Association and Business France.



Choose France is a registered trademark of the French government that promotes France's economic attractiveness internationally.

Produced by Business France



Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France's companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.

Business France has 1,500 personnel, both in France and in 55 countries throughout the world, who work with a network of partners. Since January 2019, as part of the reform of the state support system for exports, Business France has given private partners responsibility for supporting French SMEs and mid-size companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines and Singapore.

[FrenchHealthcare.fr](https://www.FrenchHealthcare.fr)

